Randomized clinical study on intratumoral BCG-cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region

Cancer Immunology Immunotherapy

Volumn 12, Issue 1, 1981, Pages 71-79

  Bier, Jürgen ^a   Rapp, Herb J ^b   Borsos, Tibor ^b   Zbar, Bert ^b   Kleinschuster, Steve ^c   Wagner, Hermann ^d   Röllinghoff, Martin ^d  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UTAH STATE UNIVERSITY   (United States)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; BCG VACCINE; TUBERCULIN;

CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MOUTH; PHARYNX; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYSTEM; SQUAMOUS CELL CARCINOMA; SURGERY; THERAPY;

EID: 0019782749     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/BF00200315     Document Type: Article

References (44)

1. Complications of BCG vaccination in neoplastic disease
2. Hepatic granulomas and other hepatic lesions associated with BCG immunotherapy for cancer
3. Immunotherapy of melanoma with intralesional BCG
4. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma
5. Maximum utilization of the life table method in analyzing survival
6. The interference phenomenon in allergic contact dermatibilis
7. Treatment of primary melanoma by intralesional vaccina before excision
8. Results of administering BCG to patients with melanoma
9. Histopathology of tumor regression after intralesional injection of Mycobacterium bovis. I. Tumor growth and metastasis
10. Granulomatous hepatitis: A complication of BCG immunotherapy
11. Regression of bovine ocular carcinoma by treatment with a mycobacterial vaccine
12. Clinical experiences in immunotherapy of cancer
13. Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guérin (MER) into cutaneous metastases of malignant melanoma
14. Serum-mediated blocking of cell-mediated anti-tumor immunity in a melanoma patient: Association with BCG immunotherapy and clinical deterioration
15. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma
16. Reactions to BCG
17. Immunotherapy of malignant melanoma
18. Clinical and histologic correlation of melanoma regression after intralesional BCG therapy
19. Regressions of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases
20. Intralesional BCG in the treatment of metastatic malignant melanoma
21. Immunotherapy of melanoma with BCG: Two fatalities following intralesional injection
22. Regional immunotherapy of lung cancer with intrapleural BCG
23. Immunological studies with human neoplasms
24. Immunologic factors in human sarcomas and melanomas: A rational basis for immunotherapy
25. Immunological aspects of neoplasia: A rational basis for immunotherapy
26. BCG immunotherapy of malignant melanoma: Summary of a seven-year experience
27. Regression of intradural malignant melanoma following intralesional injection of Mycobacterium bovis strain BCG
28. Severe thrombocytopenia following intralesional BCG therapy
29. Treatment of malignant melanoma by intratumoral injection of BCG
30. Epilesional scarification
31. Phase I–II study of intratumor immunotherapy with BCG cell wall skeleton plus P3
32. Risks of BCG intralesional therapy: An experience with melanoma
33. Active tumor immunotherapy with BCG
34. Intralesional immunotherapy of melanoma with BCG
35. Clinical and immunologic studies of dissemenated BCG infection
36. Immunotherapy in patients with melanoma
37. Immunotherapy of patients with cancer
38. Hazards and complications of BCG immunotherapy
39. Complications of BCG immunotherapy in patients with cancer
40. Generalized reaction associated with the intratumor injection of BCG
41. Phase I–II study of intralesional immunotherapy with oil-attached Mycobacterium smegmatis cell wall skeleton and trehalose dimycolate
42. Immunotherapy of cancer with cell wall skeleton of Mycobacterium bovis — Bacillus Calmette-Guérin
43. Immunotherapy of a guinea pig hepatoma with ultrasonically prepared Mycobacterial vaccines
44. Immunotherapy of cancer: regression of established intradermal tumor after intralesional injection of mycobacterial cell walls attached to oil droplets